In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).
No takes yet. Share an insight, caveat, or question.
Modi et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: